Program Description
Cardiorenal-metabolic (CRM) syndrome refers to the overlapping burden of type 2 diabetes, heart failure, and chronic kidney disease, and it is a growing clinical and economic challenge across the US health care system. Shared pathophysiologic pathways drive these conditions to progress more rapidly, contributing to hospitalizations and escalating total cost of care. However, underdiagnosis, clinical inertia, and siloed management continue to leave many patients without the coordinated, proactive care they need. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have reshaped this treatment landscape, with an expanding evidence base demonstrating cardiovascular and renal benefits that extend beyond glycemic control in patients without diabetes. As landmark cardiovascular outcomes, heart failure, and kidney disease trials have accumulated, major guidelines have converged to position SGLT2 inhibitors as foundational therapy for heart failure and chronic kidney disease, independent of hemoglobin A1c. Managed care pharmacists are central to translating this evidence into practice, as they are tasked with designing formulary and utilization management strategies that reflect guideline-directed use. When optimized, these practices can reduce administrative barriers that contribute to clinical inertia and demonstrate value through cost-effectiveness and real-world outcomes data. This session equips managed care professionals and pharmacists to assess the shared mechanisms and economic burden linking conditions in CRM syndrome, evaluate the clinical trial evidence and guideline recommendations that shape SGLT2 inhibitor use, and develop evidence-based formulary and benefit strategies that align real-world evidence with population health goals.
Target audience: Managed Care Pharmacists
Type of activity: Application
Release date: November 12, 2026
Expiration date: January 11, 2027
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, pharmacists will be able to:
- Explain shared pathophysiologic mechanisms, disease progression, and economic burden across cardiorenal-metabolic conditions with a focus on early risk identification and coordinated management
- Examine clinical trial evidence, guideline recommendations, and comparative data on sodium-glucose cotransporter-2 inhibitors in the cardiorenal-metabolic continuum for patient-centered care strategies
- Analyze evidence-based formulary and benefit strategies that incorporate real-world evidence, cost-effectiveness data, and outcomes-based frameworks
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-303-L01-P. The activity is available for CE credit through January 11, 2027.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Amanda Williams, PharmD, RPh, has the following relevant financial relationship with an ineligible company to disclose:
Employee of PBM: Gainwell Technologies.
The staff of Pharmacy Times Continuing Education™ have no relevant financial relationships with ineligible companies.
At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms